Abstract:Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of patients with deficient DNA mismatch repair (d-MMR) cancers, yet less than half of patients with metastatic colorectal cancer (mCRC) receive clinical benefit. We analyzed heterogeneity within d-MMR tumors using a multi-omics approach inclusive of percent unstable microsatellite loci (MS). Methods: We studied consecutive patients with d-MMR mCRC with available primary tumors (N=32) that were treated with an anti-PD-1 antibody at Mayo Clinic (2015-2022). Tumors were profiled using a whole exome and transcriptome platform (ImmunoID NeXT®). MSIsensor was used to calculate percent unstable microsatellite loci from whole exome sequencing data. CIBERSORT and ssGSEA were used to analyze immune gene expression in relationship to percent unstable microsatellite loci. An immune checkpoint gene expression signature was calculated as the mean expression of CD274, CTLA-4, HAVCR2, LAG-3, PDCD1, PDCD1LG2, TIGIT. Aforementioned variables were analyzed in relationship to objective tumor response (RECIST version 1.1). A Cox proportional hazards model was fit to predict progression-free survival (PFS). Results: Among 32 patients with d-MMR mCRC treated with PD-1 blockade, 16 (50%) received first-line anti-PD-1 therapy; others had > 1 prior chemotherapy regimen. Eighteen (56.3%) tumors harbored BRAFV600E, 4 (12.5%) had mutant KRAS, and median PFS was 24.6 months (95% CI: 8.4, NR) with 18 events. Neither tumor mutation burden (TMB) nor PD-L1 mRNA expression predicted PFS. Median percent unstable MS loci was 14.38 (IQR: 2.6-23.2). Patients whose tumors had higher percent unstable MS loci had significantly better PFS (Q2-4 vs Q1; HR: 0.22, 95%CI: 0.06, 0.62; P=0.003), and were associated with increased objective response (P=0.049). Tumors with higher unstable loci also had higher neoantigen clonality (R= 0.64; P= 0.0003) and increased M0 (resting) macrophages (P=0.02). Nonresponders (vs responders) to PD-1 blockade had an increased immune checkpoint expression signature (P= 0.005). Conclusion: A higher percentage of unstable microsatellite loci, associated with higher neoantigen clonality and resting macrophages, was predictive of anti-PD-1 efficacy. Furthermore, an immune checkpoint gene expression signature was associated with objective response. Citation Format: Bahar Saberzadeh-Ardestani, Oluwadunni E. Emiloju, Rondell P. Graham, Jason T. Lewis, Charles W. Abbott, Sean M. Boyle, Frank A. Sinicrope. Prediction of PD-1 treatment outcome in mismatch repair deficient metastatic colorectal cancer using a multi-omic approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 578.

Data from Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer

Biomarkers of Pathological Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair Deficiency Colorectal Cancer

The Relationship Between Mismatch Repair (MMR) Proteins Status and the Response to Conventional Neoadjuvant Therapy in Colorectal Cancer (CRC).

Association of Peripheral Blood Biomarkers with Response to Anti-PD-1 Immunotherapy for Patients with Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.

China Special Issue on Gastrointestinal Tumors‐radiological Features of Pathological Complete Response in Mismatch Repair Deficient Colorectal Cancer after Neoadjuvant PD‐1 Blockade: A Post Hoc Analysis of the PICC Phase II Trial

Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer

Supplementary Table 1 from Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer

Association of Peripheral Blood Biomarkers with Response to Anti-Pd-1 Immunotherapy for Patients with Dmmr Metastatic Colorectal Cancer: A Multicenter Cohort Study

Immune Profiling Of Microsatellite Instability-High And Polymerase Epsilon (Pole)-Mutated Metastatic Colorectal Tumors Identifies Predictors Of Response To Anti-Pd-1 Therapy

The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry

Clinical and Pathologic Response to Neoadjuvant Immunotherapy in DNA Mismatch Repair Protein-Deficient Gastroesophageal Cancers

Identification of DNA Repair-related Genes as Biomarkers Reflecting MSI, TMB, and TIL in Colorectal Cancer

Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.

Abstract 578: Prediction of PD-1 treatment outcome in mismatch repair deficient metastatic colorectal cancer using a multi-omic approach

Exploring the tumor microenvironment (TME) in patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) undergoing immune checkpoint inhibitor (ICI) therapy: Proteomic insights into immune resistance mechanisms.

PD-1 blockade boosted chemo-target therapy in cT4NxM0 pMMR/MSS colorectal cancer.

Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer

IDDF2020-ABS-0073 Proteomics Reveals That Rectal Cancer Patients with Neoadjuvant Radiochemotherapy Reach Pcr Through Immune Activation

Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study